FDA approves l-amino acid decarboxylase deficiency gene therapy
vol.24 iss.1 (2025) pp.1 Upcoming FDA approval decisions in Q1 2025
vol.24 iss.1 (2025) pp.1 Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.
(2025) 2024 FDA approvals.
(2025) Engineered T cells traverse new terrain.
(2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
(2025) DNA-PKcs inhibitor causes genomic alterations.
(2025) Human brain organoids identify glioma inhibitors.
(2025) Sodium channel blocker reduces skin inflammation.
(2025) Cough suppressant reverses lung scarring.
(2025) Base editing reduces prion protein.
(2025) J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio.
(2025) 2024 FDA approvals exceed average number but have lower sales projections.
(2025) Biopharma dealmaking in 2024.
(2025) Outlook for medicines development and use in 2025.
(2025) DLL3 draws two antibody-drug conjugate deals.
(2025) FDA approves next-generation triple therapy for cystic fibrosis.
(2025) Targeting inherited mutations to prevent metastasis.
(2025) Targeting mitophagy in neurodegenerative diseases.
(2025) Enhancing immunity during ageing by targeting interactions within the tissue environment.
(2025) FGF-based drug discovery: advances and challenges.
(2025) Voltage-gated sodium channels in excitable cells as drug targets.
(2025) Novel strategies to manage CAR-Tcell toxicity.
(2025) FDA approves first two drugs for rare Niemann-Pick disease.
vol.23 iss.11 (2024) FDA approves first monoclonal antibody for COPD.
vol.23 iss.11 (2024) Chinese innovative drug R&D trends in 2024
vol.23 iss.11 (2024) pp.2 Targeting the kynurenine pathway.
vol.23 iss.11 (2024) RNA-rewriting candidate moves into the clinic.
vol.23 iss.6 (2024) CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome.
vol.23 iss.6 (2024) Frameworks for transformational breakthroughs in RNA-based medicines.
vol.23 iss.6 (2024) Combating antimicrobial resistance in malaria, HIV and tuberculosis.
vol.23 iss.6 (2024) Opportunities and challenges for innovative and equitable healthcare.
vol.23 iss.5 (2024) RNA-editing drugs advance into clinical trials.
vol.23 iss.5 (2024) FDA approves Merck & Co's pulmonary arterial hypertension drug sotatercept.
vol.23 iss.5 (2024) FDA approves gene therapy for metachromatic leukodystrophy, the tenth for a genetic disease and the priciest yet.
vol.23 iss.5 (2024) FDA approves first complement factor D inhibitor.
vol.23 iss.5 (2024) Novel drug targets in 2023.
vol.23 iss.5 (2024) FDA new drug approvals in Q1 2024.
vol.23 iss.5 (2024) Three-step cures for autoimmune diseases?
vol.23 iss.5 (2024) The landscape and market for HIV therapies.
vol.23 iss.5 (2024) Kinase inhibitor rescues the liver.
vol.23 iss.5 (2024) AI serves up target and inhibitor for lung fibrosis.
vol.23 iss.5 (2024) Small molecule improves muscle function in myasthenia gravis.
vol.23 iss.5 (2024) Non-antibiotic drug network reveals new leads for antibiotics.
vol.23 iss.5 (2024) Antibody drug conjugate combats inflammation.
vol.23 iss.5 (2024) RNAi-based drug design: considerations and future directions.
vol.23 iss.5 (2024) The landscape of small-molecule prodrugs.
vol.23 iss.5 (2024) Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.
vol.23 iss.5 (2024) Open science in precision medicine for neurodegenerative diseases.
vol.23 iss.4 (2024) NASH field celebrates 'hurrah moment' with a first FDA drug approval for the liver disease.
vol.23 iss.4 (2024)
vol.24 iss.1 (2025) pp.1 Upcoming FDA approval decisions in Q1 2025
vol.24 iss.1 (2025) pp.1 Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.
(2025) 2024 FDA approvals.
(2025) Engineered T cells traverse new terrain.
(2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
(2025) DNA-PKcs inhibitor causes genomic alterations.
(2025) Human brain organoids identify glioma inhibitors.
(2025) Sodium channel blocker reduces skin inflammation.
(2025) Cough suppressant reverses lung scarring.
(2025) Base editing reduces prion protein.
(2025) J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio.
(2025) 2024 FDA approvals exceed average number but have lower sales projections.
(2025) Biopharma dealmaking in 2024.
(2025) Outlook for medicines development and use in 2025.
(2025) DLL3 draws two antibody-drug conjugate deals.
(2025) FDA approves next-generation triple therapy for cystic fibrosis.
(2025) Targeting inherited mutations to prevent metastasis.
(2025) Targeting mitophagy in neurodegenerative diseases.
(2025) Enhancing immunity during ageing by targeting interactions within the tissue environment.
(2025) FGF-based drug discovery: advances and challenges.
(2025) Voltage-gated sodium channels in excitable cells as drug targets.
(2025) Novel strategies to manage CAR-Tcell toxicity.
(2025) FDA approves first two drugs for rare Niemann-Pick disease.
vol.23 iss.11 (2024) FDA approves first monoclonal antibody for COPD.
vol.23 iss.11 (2024) Chinese innovative drug R&D trends in 2024
vol.23 iss.11 (2024) pp.2 Targeting the kynurenine pathway.
vol.23 iss.11 (2024) RNA-rewriting candidate moves into the clinic.
vol.23 iss.6 (2024) CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome.
vol.23 iss.6 (2024) Frameworks for transformational breakthroughs in RNA-based medicines.
vol.23 iss.6 (2024) Combating antimicrobial resistance in malaria, HIV and tuberculosis.
vol.23 iss.6 (2024) Opportunities and challenges for innovative and equitable healthcare.
vol.23 iss.5 (2024) RNA-editing drugs advance into clinical trials.
vol.23 iss.5 (2024) FDA approves Merck & Co's pulmonary arterial hypertension drug sotatercept.
vol.23 iss.5 (2024) FDA approves gene therapy for metachromatic leukodystrophy, the tenth for a genetic disease and the priciest yet.
vol.23 iss.5 (2024) FDA approves first complement factor D inhibitor.
vol.23 iss.5 (2024) Novel drug targets in 2023.
vol.23 iss.5 (2024) FDA new drug approvals in Q1 2024.
vol.23 iss.5 (2024) Three-step cures for autoimmune diseases?
vol.23 iss.5 (2024) The landscape and market for HIV therapies.
vol.23 iss.5 (2024) Kinase inhibitor rescues the liver.
vol.23 iss.5 (2024) AI serves up target and inhibitor for lung fibrosis.
vol.23 iss.5 (2024) Small molecule improves muscle function in myasthenia gravis.
vol.23 iss.5 (2024) Non-antibiotic drug network reveals new leads for antibiotics.
vol.23 iss.5 (2024) Antibody drug conjugate combats inflammation.
vol.23 iss.5 (2024) RNAi-based drug design: considerations and future directions.
vol.23 iss.5 (2024) The landscape of small-molecule prodrugs.
vol.23 iss.5 (2024) Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.
vol.23 iss.5 (2024) Open science in precision medicine for neurodegenerative diseases.
vol.23 iss.4 (2024) NASH field celebrates 'hurrah moment' with a first FDA drug approval for the liver disease.
vol.23 iss.4 (2024)
